{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:39:34Z","timestamp":1766579974356,"version":"3.41.2"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"<jats:p>We report two patients with immune checkpoint inhibitor-induced bullous pemphigoid. The modification of immunotherapy dosing enabled the continuation of their anticancer treatment and facilitated the management of skin toxicity. These findings suggest that this immune-related adverse reaction may be dose-dependent, and adjusting the treatment regimen correctly may be key to its successful management.<\/jats:p>","DOI":"10.1093\/ced\/llaf140","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:56:27Z","timestamp":1743267387000},"page":"1637-1637","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint inhibitor-induced bullous pemphigoid: evidence of dose dependency from two case studies"],"prefix":"10.1093","volume":"50","author":[{"given":"Evdoxia","family":"Panou","sequence":"first","affiliation":[{"name":"1st Department of Dermatology, Andreas Syggros Hospital for Skin Diseases, National and Kapodistrian University of\u00a0Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7139","authenticated-orcid":false,"given":"Ioannis-Alexios","family":"Koumprentziotis","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology, Andreas Syggros Hospital for Skin Diseases, National and Kapodistrian University of\u00a0Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"Queen\u2019s Hospital , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Tsimpidakis","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology, Andreas Syggros Hospital for Skin Diseases, National and Kapodistrian University of\u00a0Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Stratigos","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology, Andreas Syggros Hospital for Skin Diseases, National and Kapodistrian University of\u00a0Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology, Andreas Syggros Hospital for Skin Diseases, National and Kapodistrian University of\u00a0Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025072412171227600_llaf140-B1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"2025072412171227600_llaf140-B2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025072412171227600_llaf140-B3","doi-asserted-by":"crossref","first-page":"e007675","DOI":"10.1136\/jitc-2023-007675","article-title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"key":"2025072412171227600_llaf140-B4","doi-asserted-by":"crossref","first-page":"1748982","DOI":"10.1080\/2162402X.2020.1748982","article-title":"Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis","volume":"9","author":"Shulgin","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025072412171227600_llaf140-B5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.21781","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf140\/62749151\/llaf140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1637\/62749151\/llaf140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1637\/62749151\/llaf140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T16:17:20Z","timestamp":1753373840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/8\/1637\/8096502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":5,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf140","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,3,26]]}}}